Shanghai Pharma signs strategic R&D partnership with CAS Shanghai Institute of Materia Medica

• Shanghai Industrial Investment Holdings’ unit Shanghai Pharmaceuticals signed a strategic cooperation framework with CAS Shanghai Institute of Materia Medica.
• Partnership targets innovation drug R&D, clinical translation, project incubation, licensing, joint development, technology outsourcing.
• Focus areas include autoimmune, cardiovascular, neuropsychiatric, oncology; parties plan to co-apply for major science and technology programs.
• Collaboration also covers shared research infrastructure, AI-enabled drug discovery, proof-of-concept, investment incubation, talent exchange.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Industrial Investment Holdings Co Ltd published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.